Paclitaxel protein-bound particles for injectable suspension (albumin-bound)

DRUG2 trials

Sponsors

Mayo Clinic, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions

BioequivalenceBreast Cancer

Phase 1

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

RecruitingNCT07096869

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2025-06-26End: 2026-02-25Target: 28Updated: 2025-07-31

Phase 2

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

CompletedNCT00110084

Mayo ClinicBreast Cancer

Start: 2005-08-31End: 2010-08-31Updated: 2011-06-02